Patient reported outcomes in metastatic renal cell carcinoma patients receiving pazopanib in a community oncology setting

ISPOR Image

Targeted therapy is widely used in metastatic renal cell carcinoma (mRCC) to improve survival and health-related quality of life (HRQOL). This study investigated the impact of pazopanib on mRCC patients’ HRQOL in the US community oncology setting.

Read More